ZYUS Life Sciences Receives No Objection Letter from Health Canada for Proof-of-Concept Trial – Journal Today Internet

SASKATOON, Saskatchewan, July 30, 2024–(BUSINESS WIRE)–ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based chronicle sciences consort convergent on the utilization and utilization of newborn cannabinoid-based caregiver take candidates for discompose management, is entertained to foretell that its totally owned subsidiary, ZYUS Life Sciences Inc., has conventional a No Objection Letter (“NOL”) from Health Canada for a proof-of-concept (“POC”) effort respecting its front take candidate, Trichomylin® softgel capsules.

The NOL signifies Health Canada’s commendation that the country aggregation composed thusly farther regarding Trichomylin® softgel capsules supports progressing into a enduring population. The POC effort aims to, among another things, set the origin effectualness and practicableness of Trichomylin® softgel capsules in patients with modern cancer and medium to nonindulgent cancer-related discompose and derisk ZYUS’ previously declared Phase 2 clinical trial.

About ZYUS Life Sciences Corporation

ZYUS (TSXV: ZYUS) is a chronicle sciences consort convergent on the utilization and utilization of newborn cannabinoid-based caregiver take candidates for discompose management. Through demanding technological expedition and clinical research, ZYUS aims to bonded highbrowed concept protection, safeguarding its original therapies and bolstering investor value. ZYUS’ steady dedication extends to obtaining restrictive support of non-opioid-based caregiver solutions, in motion of transformational effect on patients’ lives. For added information, meet www.zyus.com or study us on X (formerly famous as Twitter) @ZYUSCorp.

Cautionary Note Regarding Forward-Looking Statements

This programme promulgation contains “forward-looking information” within the message of practical securities laws relating to the Company’s business, the Company’s knowledge to front clinical investigate activities, obtain restrictive support of cannabinoid-based caregiver take candidates and inform products that behave as alternatives to underway discompose direction therapies much as opioids, and derisk the previously declared Phase 2 clinical effort of Trichomylin^® softgel capsules. Any much forward-looking statements haw be identified by text much as “expects”, “anticipates”, “intends”, “contemplates”, “believes”, “projects”, “plans”, “will” and kindred expressions. Readers are cautioned not to locate unreasonable certainty on forward-looking statements. Statements about, among another things, the Company’s business, the Company’s knowledge to front clinical investigate activities, obtain restrictive support of cannabinoid-based caregiver take candidates, inform products that behave as alternatives to underway discompose direction therapies much as opioids, and derisk the previously declared Phase 2 clinical effort of Trichomylin^® softgel capsules are every forward-looking information. These statements should not be feature as guarantees of forthcoming action or results. Such statements refer famous and uncharted risks, uncertainties and another factors that haw drive actualised results, action or achievements to be materially assorted from those tacit by much statements. Although much statements are supported on management’s commonsensible assumptions, there crapper be no sureness that the Company module be healthy to attain these results. The Company assumes no domain to update or reorganise forward-looking aggregation to emit newborn events or circumstances or actualised results unless required by practical law.

Story continues

Neither the TSXV nor its Regulation Services Provider (as that constituent is circumscribed in the policies of the TSXV) accepts domain for the quality or quality of this advise release.

View maker edition on businesswire.com: https://www.businesswire.com/news/home/20240730710496/en/

Contacts

For more information, gratify contact:

ZYUS Media Inquiries
media@zyus.com
1-833-651-7723

ZYUS Investor Relations
investors@zyus.com